Route 92 Medical Announces Financing to Support Commercialization of Neurovascular Intervention Portfolio

September 23, 2024—Route 92 Medical, Inc. announced a new $50 million extension to its previously announced oversubscribed Series F financing, bringing the total raised to $82 million.

According to the privately held company, proceeds from the financing will be used to accelerate the global commercialization of its neurovascular intervention portfolio and to pursue regulatory authorizations in new geographies.

As stated in the Route 92 press release, Novo Holdings joined returning investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group in supporting the round. In connection with the investment, Noel Jee (Partner, Growth Investments at Novo Holdings US) joined the Route 92 Board of Directors.

Route 92 Medical stated that its suite of reperfusion and access systems, which feature the company’s Tenzing delivery catheter, are designed to work harmoniously as complete systems to improve the efficiency of endovascular thrombectomy procedures and quickly restore blood flow to a patient’s brain after an acute ischemic stroke.

The company’s neurovascular portfolio includes the FreeClimb 70 reperfusion system comprising the FreeClimb 70 aspiration catheter and Tenzing 7 delivery catheter; the FreeClimb 54 reperfusion system comprising the FreeClimb 54 aspiration catheter paired with a Tenzing 5 delivery catheter; and the FreeClimb 88 catheter system comprising the FreeClimb 88 catheter and Tenzing 8 delivery catheter.

In addition, the press release noted that the company announced in February 2024 that it completed enrollment in its SUMMIT MAX clinical trial, which is evaluating the safety and effectiveness of the HiPoint 88 and HiPoint 70 reperfusion catheters as part of the Monopoint reperfusion system.